Intelligent Bio Solutions: UK Partnership Drives Global Growth Ahead of U.S. Launch

Intelligent Bio Solutions (INBS), a medical technology company specializing in rapid, non-invasive testing solutions, has announced a strategic partnership with Princebuild, a leading UK construction firm. This collaboration, along with the company's recent FDA 510(k) submission, positions INBS for significant global growth and a successful entry into the U.S. market in 2025.

Princebuild, with seven sites across the UK, has adopted INBS' Intelligent Fingerprinting Drug Screening System, transitioning from saliva testing to fingerprint drug screening. This move aligns with INBS' strategic expansion in the UK construction sector and signals momentum ahead of their planned U.S. market entry in H1 2025. The partnership with Princebuild, along with over 400 accounts across 19 countries, demonstrates the commercial viability of INBS' fingerprint sweat-based drug screening technology.

The construction industry represents a substantial market opportunity, particularly as companies shift away from traditional testing methods. The recent FDA 510(k) submission in December 2024 positions INBS to tap into the lucrative US drug screening market, estimated at $4.9 billion in 2024. The timing aligns well with increasing workplace safety regulations and growing demand for non-invasive, rapid testing solutions.

INBS' fingerprint sweat-based drug screening system offers several key technological advantages over traditional methods, driving market adoption:

1. Simultaneous multi-substance detection: The system can detect multiple substances of abuse simultaneously, including cocaine, cannabis, methamphetamine, and opiates, addressing a key pain point in workplace drug screening.
2. Rapid results: The system provides results in just ten minutes, significantly faster than traditional methods, ensuring workplace safety and minimizing disruptions.
3. Non-invasive and hygienic: The system is non-invasive, making it more comfortable and less intrusive for users compared to traditional methods. Additionally, the system is hygienic, reducing the risk of cross-contamination.
4. Shorter detection window: The system focuses on recent drug use relevant to workplace safety rather than historical consumption, addressing another key pain point in workplace drug screening.
5. Respect for privacy: The system's non-invasive nature and respect for privacy align with evolving workplace cultures and employee rights considerations.



The partnership with Princebuild, along with the recent FDA 510(k) submission, positions INBS for significant global growth and a successful entry into the U.S. market in 2025. The company's fingerprint sweat-based drug screening system offers several key technological advantages over traditional methods, driving market adoption and enhancing its competitive position in the global drug screening market.

In conclusion, Intelligent Bio Solutions' strategic partnership with Princebuild and recent FDA 510(k) submission set the stage for global expansion and a successful U.S. market entry in 2025. The company's innovative fingerprint sweat-based drug screening system, with its numerous technological advantages, positions INBS as a leader in the rapidly growing global drug screening market. As the company continues to expand its customer base and enter new markets, investors can expect significant growth opportunities and a strong financial performance.